8 results about "Cns inflammation" patented technology

The present application is directed to methods and compositions for treating a condition marked by enhanced inflammation in the central nervous system (CNS). The methods comprise administering to a subject in need of treatment of enhanced inflammation in the CNS an inhibitor of an amino acid transporter in inflammatory cells present in the CNS. The compositions of the present invention relate to compositions comprising an inhibitor of an amino acid transporter in inflammatory cells, or a pharmaceutically acceptable salt thereof, wherein the composition is formulated for direct administration into the CNS of a mammal.

The invention discloses application of SB525334 in preparation of a medicine for treating / relieving central nervous system injury caused by acute Zika virus infection. Experiments prove that the SB525334 can be used as an inhibitor for inhibiting activation of a TGF / SMAD pathway, the expression quantity of Zika virus RNA in the brain is reduced, proliferation and differentiation of inflammatory cells in the brain are reduced, and the release level of inflammatory factors is reduced, so that central nervous system inflammation caused by the acute stage of Zika virus infection is relieved, central nervous system injury is relieved, and the effect of inhibiting TGF / SMAD pathway activation is achieved. The Zika virus has good treatment / alleviation potential in central nervous system injury caused by acute Zika virus infection.

The invention relates to application of NADH (nicotinamide adenine dinucleotide) in preparation of drugs for preventing or treating autism, and further provides a liposome nanoparticle oral preparation for preventing or treating autism, the NADH can reduce central nervous system inflammation, and tests prove that the NADH can remarkably reduce neural immune inflammation of autism model rats, and can be used for preventing or treating autism. The method has the advantages that the method is simple and convenient to operate and has neuroprotection and progeny rat behavioral correction capacity, social experiment defects of progeny rats are overcome, the engraving behaviors of the progeny rats are reduced, the influence of autism-related behaviors of the progeny rats is reversed, and a new scheme is provided for prevention or treatment of autism.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

The present invention relates to the use of LP17 in the preparation of an intervention drug for preventing / treating autism. The LP17 can inhibit the expression of TREM1 and reduce central nervous system inflammation. It has been verified by experiments that the early action of LP17 in neonatal mice can inhibit the accumulation of TREM1, significantly reduce neuroimmune inflammation in the autism model BTBR mice, and has the ability of neuroprotection and correction of the behavior of adult mice, improving the defects in the three-chamber social experiment of adult mice, reducing the stereotyped behavior of adult mice, reversing the impact of autism-related behaviors in adult mice, and providing clues for the development of autism.

The invention discloses formononetin derivatives and application thereof in preparation of medicines for treating central nervous system diseases, and belongs to the technical field of biological medicines. The formononetin derivative has a good effect of reducing the NO release level of BV-2 inflammatory cells, is dose-dependent, successfully enhances the anti-inflammatory activity of formononetin, almost has no cytotoxicity to BV-2 cells, and is good in safety; compared with traditional anti-inflammatory drugs, the compound has the advantages of remarkable anti-inflammatory activity and low cytotoxicity, and is expected to become a new generation of anti-central nervous inflammation drugs; on the basis of a formononetin molecular structure, the formononetin is obtained through SN2 substitution reaction, the operation is simple, the reaction conditions are controllable, and a series of derivatives can be efficiently synthesized; when being applied to preparation of the anti-central nervous system medicine, the compound has a good effect of reducing NO content of BV-2 inflammatory cells, is dose-dependent, also has a concentration-dependent inhibition effect on secretion of inflammatory factors such as IL-6 and TNF-alpha, regulates inflammatory reaction from a plurality of key links, and has a positive effect on related research of later brain diseases. The compound has a good effect of reducing NO content of BV-2 inflammatory cells, is dose-dependent and has a concentration-dependent inhibition effect on secretion of inflammatory factors such as IL-6 and TNF-alpha.

This invention discloses a compound with a pyrrolopyridine structure, its preparation method, and its pharmaceutical uses. This invention provides a novel compound with a pyrrolopyridine structure and a method for synthesizing this series of compounds. Activity studies show that the compound with the pyrrolopyridine structure possesses excellent JAK protein kinase inhibitory activity. Those skilled in the art know that JAK protein kinase plays an important role in the occurrence and development of various diseases, such as various immune diseases, myeloproliferative disorders, and central nervous system inflammatory diseases; inhibiting JAK can treat or alleviate these diseases. Therefore, the compound with the pyrrolopyridine structure provided by this invention has the potential for development into a JAK inhibitor drug and for treating or alleviating diseases by inhibiting JAK.

Providing compositions and methods for targeting inflammatory cells or activated cells to treat or improve inflammatory conditions and pain. [Solution] A method is provided for modifying the amino acid sequence and increasing the expression level of ApoA-I binding protein for treating neuropathic pain, CNS inflammation, allodynia, post-neuropathy pain, postoperative pain, chemotherapy-induced peripheral neuropathy, neurodegenerative diseases or conditions such as Alzheimer's disease, hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory eye diseases, pneumonia, asthma, HIV infection, vasculitis, atherosclerosis and cardiovascular diseases.